Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Salience Network-guided rTMS for Veterans With PTSD

NCT07886840 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07886840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Salience Network-guided rTMS for Veterans With PTSD
Lead sponsor
VA Office of Research and Development
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 1, 2027
Completion date
March 31, 2031
Enrollment
84 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • Active MRI-Guided intermittent theta burst stimulation (iTBS) ExperimentalActive MRI-Guided intermittent theta burst stimulation (iTBS)

    Participants randomized to this arm will receive 20 sessions of active intermittent theta burst stimulation (iTBS), scheduled 5 days per week for 4 weeks. When needed because of scheduling interruptions, the 20 sessions may be completed within up to 6 weeks. Treatment will be delivered to an individualized right dorsolateral prefrontal cortex target identified using MRI/fMRI-based functional connectivity.

  • Sham MRI-Guided intermittent theta burst stimulation (iTBS) Sham comparatorSham MRI-Guided intermittent theta burst stimulation (iTBS)

    Participants randomized to this arm will receive 20 sessions of sham intermittent theta burst stimulation (iTBS), scheduled 5 days per week for 4 weeks. When needed because of scheduling interruptions, the 20 sessions may be completed within up to 6 weeks. The same individualized MRI/fMRI-guided treatment location and treatment schedule will be used as in the active arm.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score Baseline and immediately following completion of treatment (approximately Week 4-6)

    The CAPS-5 is a clinician-administered interview used to assess PTSD symptoms according to DSM-5 criteria. Total PTSD symptom severity scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. The outcome is change in CAPS-5 total severity score from baseline to the post-treatment assessment.

  • Change in Anterior Insula Resting-State Functional Connectivity Baseline and immediately following completion of treatment (approximately Week 4-6)

    Resting-state functional MRI will be used to assess functional connectivity of the anterior insula (aINS). The aINS seed will be defined using the region used for personalized TMS targeting. Functional connectivity is measured as the relationship between the aINS blood-oxygen-level-dependent (BOLD) time series and BOLD time series to the brain. Higher association means higher functional connectivity. The outcome is change in aINS resting-state functional connectivity from the pre-treatment to post-treatment MRI assessment.

Lead sponsor's other trials

VA Office of Research and Development, most recent start first.

Similar trials

Same condition (Stress Disorders, Post-Traumatic) and phase, most recent start first.